Research programme: inflammation therapeutics - Akari Therapeutics

Drug Profile

Research programme: inflammation therapeutics - Akari Therapeutics

Alternative Names: Bioengineered tick salivary proteins - Akari Therapeutics; CFX-1; MCF; MRX-5; OPRX; OPT 1; OPX-1; Orally absorbed C5 inhibitor - Akari Therapeutics; Tick derived anti-inflammatory compounds - Akari Therapeutics; Tick derived proteins - Akari Therapeutics; Tissue specific proteins - Akari Therapeutics

Latest Information Update: 06 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Morria Biopharmaceuticals
  • Developer Akari Therapeutics
  • Class Anti-inflammatories; Antihistamines; Proteins
  • Mechanism of Action Arachidonic acid inhibitors; Complement system protein inhibitors; Histamine receptor antagonists; Inflammation mediator inhibitors; Leukotriene B4 inhibitors; Phospholipase A2 inhibitors; Serotonin receptor antagonists; Thromboxane A2 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation
  • No development reported Allergic conjunctivitis; Cystic fibrosis; Dry eyes; Eye-Disorders; Inflammatory bowel diseases

Most Recent Events

  • 04 Jan 2017 Preclinical trials of a C5 inhibitor in Inflammation in United Kingdom (PO)
  • 04 Jan 2017 Preclinical trials of tick derived proteins in Inflammation in United Kingdom (unspecified route)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-conjunctivitis in United Kingdom (Ophthalmic, Drops)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top